Lipocine
LPCN
Lipocine (LPCN) earnings history
Most recent quarter
- Fiscal period
- Q2 2025
- Period end
- Jun 30, 2025
- EPS actual
- −$0.41
- EPS estimate
- −$0.40
- EPS surprise
- −2.50%
- Revenue surprise
- +171.99%
- Revenue
- $622,849.00
- Revenue estimate
- $229,000.00
- Reported
- Aug 5, 2025
Earnings history
| Period | Reported | EPS estimate | EPS actual | Surprise | Revenue | Filing |
|---|---|---|---|---|---|---|
| Q2 2025 | Aug 5, 2025 | −$0.40 | −$0.41 | −2.50% | $622,849.00 | SEC |
| Q1 2025 | May 8, 2025 | −$0.35 | −$0.35 | +0.00% | $93,864.00 | SEC |
| Q4 2024 | Mar 13, 2025 | −$0.40 | $0.33 | +182.50% | $3.5M | SEC |
| Q3 2024 | Nov 7, 2024 | −$0.49 | −$0.44 | +9.28% | $0.00 | SEC |
| Q2 2024 | Aug 8, 2024 | −$0.78 | −$0.56 | +28.21% | $89,565.00 | SEC |
| Q1 2024 | May 9, 2024 | −$0.68 | $0.66 | +196.75% | $7.6M | SEC |
| Q4 2023 | Mar 7, 2024 | −$0.47 | −$0.51 | −8.51% | $200,000.00 | SEC |
| Q3 2023 | Nov 8, 2023 | −$0.60 | −$1.27 | −111.67% | −$3.1M | SEC |
| Q2 2023 | Aug 10, 2023 | −$0.64 | −$0.68 | −6.25% | $0.00 | SEC |
| Q1 2023 | May 11, 2023 | −$0.43 | −$0.68 | −60.00% | $54,990.00 | SEC |
| Q4 2022 | Mar 10, 2023 | −$0.51 | −$0.34 | +33.33% | $0.00 | SEC |
| Q3 2022 | Nov 9, 2022 | −$0.57 | −$0.51 | +10.01% | $0.00 | — |
| Q2 2022 | Aug 8, 2022 | −$0.68 | −$0.68 | +0.00% | $500,000.00 | — |
| Q1 2022 | May 9, 2022 | −$0.34 | −$0.68 | −100.00% | $0.00 | — |
| Q4 2021 | Mar 9, 2022 | −$0.17 | $2.38 | +1500.00% | $16.1M | — |
| Q3 2021 | Nov 10, 2021 | −$0.72 | −$0.51 | +29.41% | $54,994.00 | — |
| Q2 2021 | Aug 5, 2021 | −$0.85 | −$1.36 | −60.00% | $0.00 | — |
| Q1 2021 | May 6, 2021 | −$0.85 | −$0.68 | +20.00% | $0.00 | — |
| Q4 2020 | Mar 11, 2021 | −$1.08 | −$3.06 | −184.20% | $0.00 | — |
| Q3 2020 | Nov 10, 2020 | −$1.02 | −$1.19 | −16.67% | $0.00 | — |
Quarterly revenue
Frequently asked questions
When did Lipocine (LPCN) last report earnings?
Lipocine last reported on Aug 5, 2025, covering fiscal Q2 2025.
Did LPCN beat earnings estimates?
No. Lipocine reported EPS of −$0.41 for Q2 2025 against a −$0.40 estimate — a 2.50% miss.
How much revenue did LPCN report last quarter?
Lipocine reported $622,849.00 in revenue for Q2 2025, against a consensus estimate of $229,000.00.
Earnings figures may be restated, revised or corrected by the issuer. Past results do not indicate future performance.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.